Plain-English translation of NCT05594563 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Type 1 diabetes occurs when the body's immune system attacks the cells that make insulin. This trial is testing whether a medication called difluoromethylornithine () can slow down this process and help preserve the small amount of natural insulin your body may still be producing. Researchers hope this medication might help people manage their blood sugar better over time.
When type 1 diabetes is first diagnosed, many people still have some natural insulin-producing cells left in their pancreas. If this medication can protect these remaining cells from being destroyed, it might help patients require less insulin injections and achieve better long-term blood sugar control.
You likely qualify if…
You likely don't qualify if…
Over about 8 months, you will visit the research clinic multiple times for blood tests and check-ins. For the first 6 months, you will take either the study medication or a placebo pill by mouth twice daily while your diabetes care continues as usual. After stopping the medication, researchers will monitor you for another 6 weeks to see if the effects last. About two-thirds of participants will receive the active medication, while one-third will receive placebo.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States